Sovleplenib is a small molecule commercialized by Hutchmed China, with a leading Phase I program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to Globaldata, it is involved in 12 clinical trials, of which 7 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Sovleplenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The revenue for Sovleplenib is expected to reach an annual total of $87 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sovleplenib Overview
Sovleplenib (HMPL-523) is under development for the treatment of hematological cancers such as relapsed and refractory Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, coronavirus disease 2019 (COVID-19), waldenstrom macroglobulinemia, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma and immunological diseases including autoimmune disorder, primary immune thrombocytopenia, Hodgkin and non-Hodgkin lymphoma, marginal zone B-cell lymphoma and autoimmune hemolytic anemia. It is administered orally as a tablet and suspension. The drug candidate targets spleen tyrosine kinase (Syk). It was also under development for acute myeloid leukemia, multiple sclerosis, lupus erythematosus and rheumatoid arthritis. The drug candidate is a new molecular entity (NME).
Hutchmed China Overview
Hutchmed China (Hutchmed), formerly Hutchison China MediTech, is a biopharmaceutical company. It manufactures, discovers, develops, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription and consumer health drugs to hospitals in China through a direct sales force. Hutchmed is headquartered in Kowloon, Hong Kong.
The company reported revenues of (US Dollars) US$838 million for the fiscal year ended December 2023 (FY2023), an increase of 96.5% over FY2022. The operating profit of the company was US$12.6 million in FY2023, compared to an operating loss of US$407.7 million in FY2022. The net profit of the company was US$100.8 million in FY2023, compared to a net loss of US$360.8 million in FY2022.
For a complete picture of Sovleplenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
